A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinoma and (in selected centres) MRI and FDG-PET/CT Sub-studies

Trial Profile

A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinoma and (in selected centres) MRI and FDG-PET/CT Sub-studies

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Lapatinib (Primary) ; Capecitabine; Cisplatin; Epirubicin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Feb 2017 Results of primary analysis published in the Lancet Oncology.
    • 11 Oct 2016 Results (n=441) assessing safety and feasibility of adding lapatinib to perioperative ECX, presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top